trimethyloxamine has been researched along with Cardiovascular Diseases in 174 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Trimethylamine N-oxide (TMAO) is reportedly associated with deteriorating metabolic profiles and cardiovascular diseases." | 8.31 | Association of Circulating Trimethylamine-N Oxide With Malnutrition and the Risk of Coronary Artery Disease in Patients With Maintenance Hemodialysis. ( Huang, Y; Liu, J; Peng, L; Tang, C; Wang, H; Wei, X; Yuan, X, 2023) |
| "Trimethylamine (TMA) is a gut microbiota-derived metabolite which comes from diets rich of choline, betaine or L-carnitine and could be further converted to Trimethylamine-N-oxide (TMAO) in the liver." | 6.72 | Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases. ( He, S; Jiang, H; Jiang, W; Zhuo, C, 2021) |
| " Trimethylamine N-oxide (TMAO) is produced from the metabolism of dietary choline and L-carnitine by intestinal microbiota, and many studies have shown that this important product inhibits cholesterol metabolism, induces platelet aggregation and thrombosis, and promotes atherosclerosis." | 5.41 | The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. ( Cai, XC; Han, HX; He, M; Kang, XX; Liu, X; Lv, EH; Tian, JQ; Wang, YT; Wen, PB; Xiao, L; Zhang, MY; Zhen, J; Zhou, Z, 2023) |
| " More specifically, we review data on the following: (i) tryptophan metabolites and chronic kidney disease onset, illustrating the interpretation of metabolite data in the context of established biochemical pathways; (ii) trimethylamine-N-oxide and cardiovascular disease in chronic kidney disease, illustrating the integration of exogenous and endogenous inputs to the blood metabolome; and (iii) renal mitochondrial function in diabetic kidney disease and acute kidney injury, illustrating the potential for rapid translation of metabolite data for diagnostic or therapeutic aims." | 4.95 | An overview of renal metabolomics. ( Kalim, S; Rhee, EP, 2017) |
| " Trimethylamine N-oxide (TMAO) is reportedly associated with deteriorating metabolic profiles and cardiovascular diseases." | 4.31 | Association of Circulating Trimethylamine-N Oxide With Malnutrition and the Risk of Coronary Artery Disease in Patients With Maintenance Hemodialysis. ( Huang, Y; Liu, J; Peng, L; Tang, C; Wang, H; Wei, X; Yuan, X, 2023) |
| "Trimethylamine-N-oxide (TMAO) has been suggested as a marker and mediator of cardiovascular diseases." | 3.91 | TMA, A Forgotten Uremic Toxin, but Not TMAO, Is Involved in Cardiovascular Pathology. ( Bielak-Zmijewska, A; Filipiak, K; Gasecka, A; Hering, D; Hołyst, R; Jaworska, K; Kapłon-Cieślicka, A; Konwerski, M; Mosieniak, G; Pilz, M; Sikora, E; Ufnal, M, 2019) |
| " Furthermore, unlike chronic dietary choline, TML supplementation in mice failed to elevate plasma TMAO or heighten thrombosis potential in vivo." | 3.88 | Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. ( Allayee, H; Buffa, JA; Cajka, T; DiDonato, JA; Fiehn, O; Gu, X; Han, Y; Hartiala, JA; Hazen, SL; Hurd, AG; Kerby, RL; Li, L; Li, XS; Lüscher, TF; Nemet, I; Obeid, S; Rey, FE; Roberts, AB; Romano, KA; Shahen, CJ; Skye, SM; Tang, WHW; Wagner, MA; Wang, Z; Wu, Y, 2018) |
| "There is a dose-response relationship between TMAO levels and NCDs progression." | 3.01 | Trimethylamine N-Oxide as a Potential Risk Factor for Non-communicable Diseases: A Systematic Review. ( Ejtahed, HS; Hasani-Ranjbar, S; Hoseini-Tavassol, Z; Larijani, B, 2023) |
| " We aimed to assess the correlation between circulating TMAO concentration and the risk of all-cause and cardiovascular death in CKD patients of different dialysis statuses and different races by dose-response analyses, and the underlying mechanisms were also explored by analyzing the correlations of TMAO with glomerular filtration rate (GFR) and inflammation." | 3.01 | Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis. ( Guo, J; Li, Y; Liu, W; Liu, Y; Lu, H; Zhang, M; Zheng, H, 2023) |
| "Atherosclerotic cardiovascular diseases are preferential targets of healthy diet and preventive medicine partially through strategies to improve lipid profile and counteract oxidative metabolites." | 2.90 | Lactofermented Annurca Apple Puree as a Functional Food Indicated for the Control of Plasma Lipid and Oxidative Amine Levels: Results from a Randomised Clinical Trial. ( Bocchino, B; Buonomo, G; Caruso, D; Ciampaglia, R; D'Avino, M; Maisto, M; Novellino, E; Schisano, C; Tenore, GC, 2019) |
| "Chronic obstructive pulmonary disease (COPD) is a prevalent disease worldwide with a high associated risk for cardiovascular disease and death due to an infectious cause." | 2.87 | Gut, microbiota-dependent trimethylamine-N-oxide is associated with long-term all-cause mortality in patients with exacerbated chronic obstructive pulmonary disease. ( Bernasconi, L; Christ-Crain, M; Henzen, C; Hoess, C; Huber, A; Mueller, B; Nickler, M; Ottiger, M; Schuetz, P; Steuer, C; Thomann, R; Zimmerli, W, 2018) |
| "The changes of intestinal bacteria in ESRD patients have contributed to the accumulation of gut-derived uremic toxins such as TMAO, indoxyl sulfate and indole-3-acetic acid." | 2.82 | [Gut-derived uremic toxin trimethylamine-N-oxide in cardiovascular disease under end-stage renal disease: an injury mechanism and therapeutic target]. ( Ren, Y; Wang, Z; Xue, J, 2022) |
| "The aim of this systematic review and meta-analysis was to summarize evidence of the relationship between circulating TMAO levels and risk of hypertension and increased serum lipids in a dose-response and 2-class meta-analysis of discrete and continuous variables." | 2.72 | Gut microbiota-associated trimethylamine N-oxide and increased cardiometabolic risk in adults: a systematic review and dose-response meta-analysis. ( Abbasalizad Farhangi, M; Vajdi, M, 2021) |
| "Trimethylamine (TMA) is a gut microbiota-derived metabolite which comes from diets rich of choline, betaine or L-carnitine and could be further converted to Trimethylamine-N-oxide (TMAO) in the liver." | 2.72 | Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases. ( He, S; Jiang, H; Jiang, W; Zhuo, C, 2021) |
| "Phenylacetylglutamine, for example, was recently shown to promote adverse cardiovascular phenotypes in the host via interaction with multiple ARs (adrenergic receptors)-a class of key receptors that regulate cardiovascular homeostasis." | 2.66 | Gut Microbiota and Cardiovascular Disease. ( Hazen, SL; Weeks, TL; Witkowski, M, 2020) |
| "Choline is a water-soluble nutrient essential for human life." | 2.66 | The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. ( Allison, J; Arboleya, S; Arias, JL; Arias, N; Gueimonde, M; Higarza, SG; Kaliszewska, A, 2020) |
| "0001) according to the dose-response meta-analysis." | 2.66 | The Gut Microbial Metabolite Trimethylamine N-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis. ( Fan, H; Ge, X; Liu, G; Xi, X; Xu, Z; Yu, P; Zheng, L; Zhou, X; Zhuang, R, 2020) |
| "Dysbiosis is associated with intestinal inflammation and reduced integrity of the gut barrier, which in turn increases circulating levels of bacterial structural components and microbial metabolites that may facilitate the development of CVD." | 2.58 | The gut microbiota as a novel regulator of cardiovascular function and disease. ( Battson, ML; Gentile, CL; Lee, DM; Weir, TL, 2018) |
| " Dose-response meta-analysis revealed that the relative risk (RR) for all-cause mortality increased by 7." | 2.55 | Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. ( Esposito, G; Franzone, A; Gargiulo, G; Giugliano, G; Perrino, C; Sannino, A; Schiattarella, GG; Toscano, E; Trimarco, B, 2017) |
| "This case-cohort study included Chronic Renal Insufficiency Cohort participants with baseline diabetes, estimated glomerular filtration rate <60 mL/min/1." | 1.91 | Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. ( Anderson, AH; Bhat, Z; Brown, J; Brunengraber, H; Charleston, J; Chen, J; Feldman, HI; He, J; Hostetter, TH; Hsu, CY; Ix, JH; Kimmel, PL; Mehta, R; Rao, P; Sapa, H; Schelling, JR; Schrauben, SJ; Seegmiller, JC; Shafi, T; Shlipak, MG; Townsend, R; Vasan, RS; Xie, D; Zhang, X, 2023) |
| "Vascular dysfunction: develops progressively with ageing; increases the risk of cardiovascular diseases (CVD); and is characterized by endothelial dysfunction and arterial stiffening, which are primarily mediated by superoxide-driven oxidative stress and consequently reduced nitric oxide (NO) bioavailability and arterial structural changes." | 1.72 | Initiation of 3,3-dimethyl-1-butanol at midlife prevents endothelial dysfunction and attenuates in vivo aortic stiffening with ageing in mice. ( Brunt, VE; Casso, AG; Clayton, ZS; Davy, KP; Gioscia-Ryan, RA; Greenberg, NT; Hutton, DA; Neilson, AP; Seals, DR; VanDongen, NS; Ziemba, BP, 2022) |
| "Atherosclerosis is a hallmark of cardiovascular disease, and lifestyle strongly impacts its onset and progression." | 1.72 | TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis. ( Blanco, R; Daimiel, L; Dávalos, A; Díez-Ricote, L; Micó, V; Ordovás, JM; Ruiz-Valderrey, P; Tomé-Carneiro, J, 2022) |
| "Choline was associated with higher systolic blood pressure, TGs, lipopolysaccharide-binding protein, and lower HDL cholesterol (P ranging from <0." | 1.56 | Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. ( Cheng, I; Franke, AA; Fu, BC; Hullar, MAJ; Lampe, JW; Le Marchand, L; Lim, U; Madeleine, MM; Monroe, KR; Randolph, TW; Shepherd, JA; Wilkens, LR, 2020) |
| " Dose-response analysis revealed a linear association between the TMAO concentration and the OR for frailty." | 1.56 | Trimethylamine N-Oxide, a Gut Microbiota-Dependent Metabolite, is Associated with Frailty in Older Adults with Cardiovascular Disease. ( Cui, LL; Guo, D; He, W; Liu, JP; Luo, Y; Sun, N; Wang, H; Yang, JF; Yao, SM; Zheng, PP, 2020) |
| "Furthermore, cardiovascular diseases are associated with disturbances in water-electrolyte balance which produce changes in plasma osmolarity." | 1.51 | Is increased plasma TMAO a compensatory response to hydrostatic and osmotic stress in cardiovascular diseases? ( Nowiński, A; Ufnal, M, 2019) |
| "L-carnitine has been advertised as a fat-lowering and performance-enhancing supplement, although scientific evidence for its effectiveness is lacking." | 1.46 | The influence of a chronic L-carnitine administration on the plasma metabolome of male Fischer 344 rats. ( Egert, B; Empl, MT; Frommherz, L; Krüger, R; Kulling, SE; Steinberg, P; Weinert, CH, 2017) |
| "Betaine is a major osmolyte, also important in methyl group metabolism." | 1.40 | Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study. ( Atkinson, W; Bellamy, D; Chambers, ST; Elmslie, JL; Frampton, CM; George, PM; Ho, M; Lever, M; McEntyre, CJ; Molyneux, SL; Richards, AM; Slow, S; Troughton, RW; Young, JM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 85 (48.85) | 24.3611 |
| 2020's | 89 (51.15) | 2.80 |
| Authors | Studies |
|---|---|
| Annunziata, G | 2 |
| Ciampaglia, R | 3 |
| Capò, X | 1 |
| Guerra, F | 1 |
| Sureda, A | 1 |
| Tenore, GC | 3 |
| Novellino, E | 3 |
| Xie, G | 1 |
| Yan, A | 1 |
| Lin, P | 1 |
| Wang, Y | 3 |
| Guo, L | 1 |
| Ringel, C | 1 |
| Dittrich, J | 1 |
| Gaudl, A | 1 |
| Schellong, P | 1 |
| Beuchel, CF | 1 |
| Baber, R | 1 |
| Beutner, F | 1 |
| Teren, A | 1 |
| Engel, C | 1 |
| Wirkner, K | 1 |
| Thiele, H | 1 |
| Büttner, P | 1 |
| Löffler, M | 1 |
| Scholz, M | 1 |
| Thiery, J | 1 |
| Ceglarek, U | 1 |
| Díez-Ricote, L | 2 |
| Ruiz-Valderrey, P | 2 |
| Micó, V | 2 |
| Blanco-Rojo, R | 1 |
| Tomé-Carneiro, J | 2 |
| Dávalos, A | 2 |
| Ordovás, JM | 2 |
| Daimiel, L | 2 |
| Chang, D | 1 |
| Xu, X | 2 |
| Yang, Z | 1 |
| Ma, T | 1 |
| Nie, J | 1 |
| Dong, J | 2 |
| Kang, JW | 1 |
| Zivkovic, AM | 1 |
| Chen, G | 1 |
| He, L | 1 |
| Dou, X | 1 |
| Liu, T | 1 |
| Nandi, S | 1 |
| Pyne, A | 1 |
| Layek, S | 1 |
| Arora, C | 1 |
| Sarkar, N | 1 |
| Buffa, JA | 3 |
| Romano, KA | 2 |
| Copeland, MF | 1 |
| Cody, DB | 1 |
| Zhu, W | 2 |
| Galvez, R | 1 |
| Fu, X | 4 |
| Ward, K | 1 |
| Ferrell, M | 1 |
| Dai, HJ | 1 |
| Skye, S | 1 |
| Hu, P | 1 |
| Li, L | 3 |
| Parlov, M | 1 |
| McMillan, A | 1 |
| Wei, X | 2 |
| Nemet, I | 3 |
| Koeth, RA | 3 |
| Li, XS | 7 |
| Wang, Z | 16 |
| Sangwan, N | 1 |
| Hajjar, AM | 1 |
| Dwidar, M | 1 |
| Weeks, TL | 2 |
| Bergeron, N | 2 |
| Krauss, RM | 2 |
| Tang, WHW | 7 |
| Rey, FE | 3 |
| DiDonato, JA | 6 |
| Gogonea, V | 1 |
| Gerberick, GF | 1 |
| Garcia-Garcia, JC | 1 |
| Hazen, SL | 19 |
| Amrein, M | 1 |
| Walter, J | 1 |
| Zimmermann, T | 1 |
| Strebel, I | 1 |
| Honegger, U | 1 |
| Leu, K | 1 |
| Schäfer, I | 1 |
| Twerenbold, R | 1 |
| Puelacher, C | 1 |
| Glarner, N | 1 |
| Nestelberger, T | 1 |
| Koechlin, L | 1 |
| Ceresa, B | 1 |
| Haaf, P | 1 |
| Bakula, A | 1 |
| Zellweger, M | 1 |
| Mueller, C | 1 |
| Li, D | 1 |
| Lu, Y | 5 |
| Yuan, S | 1 |
| Cai, X | 1 |
| He, Y | 3 |
| Chen, J | 3 |
| Wu, Q | 1 |
| He, D | 1 |
| Fang, A | 1 |
| Bo, Y | 1 |
| Song, P | 1 |
| Bogaert, D | 1 |
| Tsilidis, K | 1 |
| Larsson, SC | 1 |
| Yu, H | 1 |
| Zhu, H | 1 |
| Theodoratou, E | 1 |
| Zhu, Y | 5 |
| Li, X | 3 |
| Sapa, H | 2 |
| Gutiérrez, OM | 1 |
| Shlipak, MG | 2 |
| Katz, R | 1 |
| Ix, JH | 2 |
| Sarnak, MJ | 1 |
| Cushman, M | 1 |
| Rhee, EP | 2 |
| Kimmel, PL | 2 |
| Vasan, RS | 2 |
| Schrauben, SJ | 2 |
| Feldman, HI | 2 |
| Seegmiller, JC | 2 |
| Brunengraber, H | 2 |
| Hostetter, TH | 3 |
| Schelling, JR | 2 |
| Konieczny, RA | 2 |
| Kuliczkowski, W | 3 |
| Bean, LD | 1 |
| Wing, JJ | 1 |
| Harris, RE | 1 |
| Smart, SM | 1 |
| Raman, SV | 1 |
| Milks, MW | 1 |
| Cantero, MA | 1 |
| Guedes, MRA | 1 |
| Fernandes, R | 1 |
| Lollo, PCB | 1 |
| Fretts, AM | 1 |
| Jensen, P | 1 |
| Budoff, M | 3 |
| Sitlani, CM | 1 |
| Wang, M | 3 |
| de Oliveira Otto, MC | 3 |
| Lee, Y | 2 |
| Psaty, BM | 3 |
| Siscovick, DS | 3 |
| Sotoodehnia, N | 3 |
| Lai, H | 1 |
| Lemaitre, RN | 3 |
| Mozaffarian, D | 3 |
| Żurawska-Płaksej, E | 2 |
| Kaaz, K | 2 |
| Czapor-Irzabek, H | 2 |
| Bombała, W | 2 |
| Mysiak, A | 2 |
| Li, DY | 2 |
| Chaikijurajai, T | 1 |
| Lai, HTM | 1 |
| Fretts, A | 2 |
| McKnight, B | 1 |
| Konieczny, R | 1 |
| Hsu, BG | 1 |
| Wang, CH | 1 |
| Lin, YL | 1 |
| Lai, YH | 1 |
| Tsai, JP | 1 |
| Ren, Y | 1 |
| Xue, J | 2 |
| Buawangpong, N | 1 |
| Pinyopornpanish, K | 1 |
| Phrommintikul, A | 2 |
| Chindapan, N | 1 |
| Devahastin, S | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Casso, AG | 1 |
| VanDongen, NS | 1 |
| Gioscia-Ryan, RA | 1 |
| Clayton, ZS | 1 |
| Greenberg, NT | 1 |
| Ziemba, BP | 1 |
| Hutton, DA | 1 |
| Neilson, AP | 2 |
| Davy, KP | 2 |
| Seals, DR | 1 |
| Brunt, VE | 1 |
| Zhu, B | 1 |
| Ren, H | 1 |
| Xie, F | 1 |
| An, Y | 1 |
| Tan, Y | 1 |
| Huang, Y | 2 |
| Zhang, H | 2 |
| Fan, X | 1 |
| Wang, J | 1 |
| Yin, Y | 1 |
| Zhang, Y | 1 |
| Shi, K | 1 |
| Yu, F | 1 |
| Blanco, R | 1 |
| Hoseini-Tavassol, Z | 1 |
| Ejtahed, HS | 1 |
| Larijani, B | 1 |
| Hasani-Ranjbar, S | 1 |
| Saaoud, F | 4 |
| Liu, L | 3 |
| Xu, K | 3 |
| Cueto, R | 3 |
| Shao, Y | 3 |
| Sun, Y | 5 |
| Snyder, NW | 3 |
| Wu, S | 3 |
| Yang, L | 3 |
| Zhou, Y | 3 |
| Williams, DL | 3 |
| Li, C | 3 |
| Martinez, L | 3 |
| Vazquez-Padron, RI | 3 |
| Zhao, H | 3 |
| Jiang, X | 3 |
| Wang, H | 6 |
| Yang, X | 4 |
| Cao, H | 3 |
| Hu, G | 3 |
| Zhang, Q | 3 |
| Zheng, L | 5 |
| Yuan, X | 1 |
| Liu, J | 2 |
| Tang, C | 1 |
| Peng, L | 1 |
| Canyelles, M | 1 |
| Borràs, C | 1 |
| Rotllan, N | 1 |
| Tondo, M | 1 |
| Escolà-Gil, JC | 1 |
| Blanco-Vaca, F | 1 |
| Tacconi, E | 1 |
| Palma, G | 1 |
| De Biase, D | 1 |
| Luciano, A | 1 |
| Barbieri, M | 1 |
| de Nigris, F | 1 |
| Bruzzese, F | 1 |
| Zhen, J | 1 |
| Zhou, Z | 1 |
| He, M | 2 |
| Han, HX | 1 |
| Lv, EH | 1 |
| Wen, PB | 1 |
| Liu, X | 2 |
| Wang, YT | 1 |
| Cai, XC | 1 |
| Tian, JQ | 1 |
| Zhang, MY | 1 |
| Xiao, L | 1 |
| Kang, XX | 1 |
| Çelikkol, A | 1 |
| Mercan, R | 1 |
| Güzel, S | 1 |
| Yılmaz, A | 1 |
| Mu, HN | 1 |
| Zhao, XH | 1 |
| Zhang, RR | 1 |
| Li, ZY | 1 |
| Yang, RY | 1 |
| Wang, SM | 1 |
| Li, HX | 1 |
| Chen, WX | 1 |
| Naghipour, S | 2 |
| Fisher, JJ | 1 |
| Perkins, AV | 1 |
| Peart, JN | 2 |
| Headrick, JP | 2 |
| Toit, EFD | 1 |
| Lei, D | 1 |
| Yu, W | 1 |
| Liu, Y | 4 |
| Jiang, Y | 1 |
| Lv, J | 1 |
| Li, Y | 4 |
| Xie, D | 1 |
| Zhang, X | 3 |
| Anderson, AH | 1 |
| Hsu, CY | 1 |
| Shafi, T | 2 |
| Mehta, R | 1 |
| Bhat, Z | 1 |
| Brown, J | 1 |
| Charleston, J | 1 |
| He, J | 1 |
| Rao, P | 1 |
| Townsend, R | 1 |
| Lu, H | 1 |
| Guo, J | 1 |
| Zhang, M | 1 |
| Zheng, H | 1 |
| Liu, W | 1 |
| Yang, Y | 1 |
| Karampoor, S | 1 |
| Mirzaei, R | 1 |
| Borozdkin, L | 1 |
| Zhu, P | 2 |
| Hemmati, M | 1 |
| Kashanipoor, S | 1 |
| Mazaheri, P | 1 |
| Alibabaei, F | 1 |
| Babaeizad, A | 1 |
| Asli, S | 1 |
| Mohammadi, S | 1 |
| Gorgin, AH | 1 |
| Ghods, K | 1 |
| Yousefi, B | 1 |
| Eslami, M | 1 |
| Belli, M | 1 |
| Barone, L | 1 |
| Longo, S | 1 |
| Prandi, FR | 1 |
| Lecis, D | 1 |
| Mollace, R | 1 |
| Margonato, D | 1 |
| Muscoli, S | 1 |
| Sergi, D | 1 |
| Federici, M | 1 |
| Barillà, F | 1 |
| Lee, H | 1 |
| An, JP | 1 |
| Chan, MM | 1 |
| Fong, D | 1 |
| Jaworska, K | 2 |
| Konop, M | 1 |
| Hutsch, T | 1 |
| Perlejewski, K | 1 |
| Radkowski, M | 1 |
| Grochowska, M | 1 |
| Bielak-Zmijewska, A | 2 |
| Mosieniak, G | 2 |
| Sikora, E | 2 |
| Ufnal, M | 5 |
| Hering, D | 1 |
| Pilz, M | 1 |
| Konwerski, M | 1 |
| Gasecka, A | 1 |
| Kapłon-Cieślicka, A | 1 |
| Filipiak, K | 1 |
| Hołyst, R | 1 |
| Mitchell, SM | 1 |
| Milan, AM | 1 |
| Mitchell, CJ | 1 |
| Gillies, NA | 1 |
| D'Souza, RF | 1 |
| Zeng, N | 1 |
| Ramzan, F | 1 |
| Sharma, P | 1 |
| Knowles, SO | 1 |
| Roy, NC | 1 |
| Sjödin, A | 1 |
| Wagner, KH | 1 |
| Zeisel, SH | 1 |
| Cameron-Smith, D | 1 |
| Eyupoglu, ND | 1 |
| Caliskan Guzelce, E | 1 |
| Acikgoz, A | 1 |
| Uyanik, E | 1 |
| Bjørndal, B | 1 |
| Berge, RK | 4 |
| Svardal, A | 3 |
| Yildiz, BO | 1 |
| Kasahara, K | 1 |
| Moludi, J | 1 |
| Maleki, V | 1 |
| Jafari-Vayghyan, H | 1 |
| Vaghef-Mehrabany, E | 1 |
| Alizadeh, M | 1 |
| Dai, Q | 1 |
| Berger, M | 1 |
| Kleber, ME | 1 |
| Delgado, GE | 1 |
| März, W | 1 |
| Andreas, M | 1 |
| Hellstern, P | 1 |
| Marx, N | 1 |
| Schuett, KA | 1 |
| Montrucchio, C | 1 |
| De Nicolò, A | 1 |
| D'Ettorre, G | 1 |
| D'Ascenzo, F | 1 |
| Lazzaro, A | 1 |
| Tettoni, M | 1 |
| D'Avolio, A | 1 |
| Bonora, S | 1 |
| Celani, L | 1 |
| Di Perri, G | 1 |
| Calcagno, A | 1 |
| Fu, BC | 1 |
| Hullar, MAJ | 1 |
| Randolph, TW | 1 |
| Franke, AA | 1 |
| Monroe, KR | 1 |
| Cheng, I | 1 |
| Wilkens, LR | 1 |
| Shepherd, JA | 1 |
| Madeleine, MM | 1 |
| Le Marchand, L | 1 |
| Lim, U | 1 |
| Lampe, JW | 1 |
| Yue, SJ | 1 |
| Wang, WX | 1 |
| Tao, HJ | 1 |
| Bai, X | 1 |
| Huang, YX | 1 |
| Zhang, S | 1 |
| Shen, X | 1 |
| Liu, JP | 2 |
| Tang, YP | 1 |
| Fadhlaoui, K | 1 |
| Arnal, ME | 1 |
| Martineau, M | 1 |
| Camponova, P | 1 |
| Ollivier, B | 1 |
| O'Toole, PW | 1 |
| Brugère, JF | 1 |
| Croyal, M | 1 |
| Saulnier, PJ | 1 |
| Aguesse, A | 1 |
| Gand, E | 1 |
| Ragot, S | 1 |
| Roussel, R | 1 |
| Halimi, JM | 1 |
| Ducrocq, G | 1 |
| Cariou, B | 1 |
| Montaigne, D | 1 |
| Wargny, M | 1 |
| Krempf, M | 1 |
| Hadjadj, S | 1 |
| Meyer, KA | 1 |
| Papandreou, C | 1 |
| Moré, M | 1 |
| Bellamine, A | 1 |
| Dannenberg, L | 1 |
| Zikeli, D | 1 |
| Benkhoff, M | 1 |
| Ahlbrecht, S | 1 |
| Kelm, M | 1 |
| Levkau, B | 1 |
| Polzin, A | 1 |
| Özcan-Ekşi, EE | 1 |
| Ekşi, MŞ | 1 |
| Turgut, VU | 1 |
| Canbolat, Ç | 1 |
| Pamir, MN | 1 |
| Nocentini, A | 1 |
| Del Prete, S | 1 |
| Mastrolorenzo, MD | 1 |
| Donald, WA | 1 |
| Capasso, C | 1 |
| Supuran, CT | 1 |
| Zheng, Y | 4 |
| Tang, Z | 1 |
| You, L | 1 |
| Wu, Y | 5 |
| Bin Waleed, K | 1 |
| Liu, Q | 1 |
| Zeng, F | 1 |
| Tu, H | 1 |
| Wei, Y | 1 |
| Xu, S | 1 |
| Zhang, Z | 2 |
| Rongfeng, Y | 1 |
| Fan, A | 1 |
| Altaf, A | 1 |
| Chang, J | 1 |
| Wang, L | 1 |
| Winther, SA | 2 |
| Rossing, P | 2 |
| Shui, X | 1 |
| Liang, Z | 1 |
| Huang, Z | 1 |
| Qi, Y | 1 |
| Chen, C | 1 |
| Luo, H | 1 |
| Lei, W | 1 |
| Cox, AJ | 1 |
| Du Toit, EF | 1 |
| Cho, CE | 1 |
| Aardema, NDJ | 1 |
| Bunnell, ML | 1 |
| Larson, DP | 1 |
| Aguilar, SS | 1 |
| Bergeson, JR | 1 |
| Malysheva, OV | 2 |
| Caudill, MA | 2 |
| Lefevre, M | 1 |
| Witkowski, M | 1 |
| Arias, N | 1 |
| Arboleya, S | 1 |
| Allison, J | 1 |
| Kaliszewska, A | 1 |
| Higarza, SG | 1 |
| Gueimonde, M | 1 |
| Arias, JL | 1 |
| Guasti, L | 1 |
| Galliazzo, S | 1 |
| Molaro, M | 1 |
| Visconti, E | 1 |
| Pennella, B | 1 |
| Gaudio, GV | 1 |
| Lupi, A | 1 |
| Grandi, AM | 1 |
| Squizzato, A | 1 |
| Crimarco, A | 1 |
| Springfield, S | 1 |
| Petlura, C | 1 |
| Streaty, T | 1 |
| Cunanan, K | 1 |
| Lee, J | 1 |
| Fielding-Singh, P | 1 |
| Carter, MM | 1 |
| Topf, MA | 1 |
| Wastyk, HC | 1 |
| Sonnenburg, ED | 1 |
| Sonnenburg, JL | 1 |
| Gardner, CD | 1 |
| Ravid, JD | 1 |
| Chitalia, VC | 1 |
| Zhang, P | 1 |
| Zou, JZ | 1 |
| Tan, X | 1 |
| Xiang, FF | 1 |
| Shen, B | 1 |
| Hu, JC | 1 |
| Wang, JL | 1 |
| Wang, YQ | 1 |
| Yu, JB | 1 |
| Nie, YX | 1 |
| Chen, XH | 1 |
| Yu, JW | 1 |
| Lv, WL | 1 |
| Xie, YQ | 1 |
| Cao, XS | 1 |
| Ding, XQ | 1 |
| He, W | 1 |
| Luo, Y | 1 |
| Sun, N | 1 |
| Guo, D | 1 |
| Cui, LL | 1 |
| Zheng, PP | 1 |
| Yao, SM | 1 |
| Yang, JF | 1 |
| Zhou, W | 1 |
| Cheng, Y | 1 |
| Nasser, MI | 1 |
| Zhao, M | 1 |
| Rajendiran, E | 1 |
| Ramadass, B | 1 |
| Ramprasath, V | 1 |
| Bordoni, L | 1 |
| Samulak, JJ | 1 |
| Sawicka, AK | 1 |
| Pelikant-Malecka, I | 1 |
| Radulska, A | 1 |
| Lewicki, L | 1 |
| Kalinowski, L | 1 |
| Gabbianelli, R | 1 |
| Olek, RA | 1 |
| Ebert, T | 1 |
| Painer, J | 1 |
| Bergman, P | 4 |
| Qureshi, AR | 2 |
| Giroud, S | 1 |
| Stalder, G | 1 |
| Kublickiene, K | 1 |
| Göritz, F | 1 |
| Vetter, S | 1 |
| Bieber, C | 1 |
| Fröbert, O | 1 |
| Arnemo, JM | 1 |
| Zedrosser, A | 1 |
| Redtenbacher, I | 1 |
| Shiels, PG | 1 |
| Johnson, RJ | 1 |
| Stenvinkel, P | 4 |
| Abbasalizad Farhangi, M | 1 |
| Vajdi, M | 1 |
| Tan, CP | 1 |
| Xu, YJ | 1 |
| Duttaroy, AK | 1 |
| Iglesias-Carres, L | 1 |
| Hughes, MD | 1 |
| Steele, CN | 1 |
| Ponder, MA | 1 |
| Thomas, MS | 1 |
| Fernandez, ML | 2 |
| Øllgaard, JC | 1 |
| Hansen, TW | 1 |
| von Scholten, BJ | 1 |
| Reinhard, H | 1 |
| Ahluwalia, TS | 1 |
| Gæde, P | 1 |
| Parving, HH | 1 |
| Hazen, S | 1 |
| Pedersen, O | 1 |
| Mei, Z | 1 |
| Chen, GC | 1 |
| Usyk, M | 1 |
| Yu, B | 1 |
| Baeza, YV | 1 |
| Humphrey, G | 1 |
| Benitez, RS | 1 |
| Li, J | 3 |
| Williams-Nguyen, JS | 1 |
| Daviglus, ML | 1 |
| Hou, L | 1 |
| Cai, J | 1 |
| Knight, R | 2 |
| Burk, RD | 1 |
| Boerwinkle, E | 1 |
| Kaplan, RC | 1 |
| Qi, Q | 1 |
| Swanepoel, I | 1 |
| Roberts, A | 1 |
| Brauns, C | 1 |
| Chaliha, DR | 1 |
| Papa, V | 1 |
| Palmer, RD | 1 |
| Vaccarezza, M | 1 |
| Tilves, C | 1 |
| Mueller, NT | 1 |
| Yamashita, T | 1 |
| Yoshida, N | 1 |
| Emoto, T | 1 |
| Saito, Y | 1 |
| Hirata, KI | 1 |
| Ivey, KL | 1 |
| Wang, DD | 2 |
| Wilkinson, JE | 1 |
| Franke, A | 1 |
| Lee, KH | 1 |
| Chan, A | 1 |
| Huttenhower, C | 1 |
| Hu, FB | 3 |
| Rimm, EB | 2 |
| Sun, Q | 1 |
| He, S | 1 |
| Jiang, H | 1 |
| Zhuo, C | 1 |
| Jiang, W | 1 |
| Taguchi, K | 1 |
| Fukami, K | 1 |
| Elias, BC | 1 |
| Brooks, CR | 1 |
| Senthong, V | 2 |
| Kiatchoosakun, S | 1 |
| Wongvipaporn, C | 1 |
| Phetcharaburanin, J | 1 |
| Tatsanavivat, P | 1 |
| Sritara, P | 1 |
| He, JQ | 1 |
| Hove-Skovsgaard, M | 1 |
| Gaardbo, JC | 1 |
| Kolte, L | 1 |
| Winding, K | 1 |
| Seljeflot, I | 1 |
| Gerstoft, J | 1 |
| Ullum, H | 1 |
| Trøseid, M | 4 |
| Nielsen, SD | 2 |
| Fernandez-Prado, R | 1 |
| Esteras, R | 1 |
| Perez-Gomez, MV | 1 |
| Gracia-Iguacel, C | 1 |
| Gonzalez-Parra, E | 1 |
| Sanz, AB | 1 |
| Ortiz, A | 1 |
| Sanchez-Niño, MD | 1 |
| Garcia, E | 1 |
| Wolak-Dinsmore, J | 1 |
| Bennett, DW | 1 |
| Connelly, MA | 1 |
| Otvos, JD | 1 |
| Jeyarajah, EJ | 1 |
| Haissman, JM | 1 |
| Haugaard, AK | 1 |
| Ostrowski, SR | 1 |
| Hov, JR | 2 |
| He, Z | 1 |
| Chen, ZY | 1 |
| Heianza, Y | 1 |
| Ma, W | 1 |
| Manson, JE | 2 |
| Rexrode, KM | 2 |
| Qi, L | 2 |
| Krüger, R | 2 |
| Merz, B | 1 |
| Rist, MJ | 1 |
| Ferrario, PG | 1 |
| Bub, A | 1 |
| Kulling, SE | 2 |
| Watzl, B | 1 |
| Qi, J | 1 |
| You, T | 1 |
| Pan, T | 1 |
| Xiang, L | 1 |
| Han, Y | 2 |
| Zhu, L | 1 |
| Tomlinson, JAP | 1 |
| Wheeler, DC | 1 |
| Ottiger, M | 1 |
| Nickler, M | 1 |
| Steuer, C | 1 |
| Bernasconi, L | 1 |
| Huber, A | 1 |
| Christ-Crain, M | 1 |
| Henzen, C | 1 |
| Hoess, C | 1 |
| Thomann, R | 1 |
| Zimmerli, W | 1 |
| Mueller, B | 1 |
| Schuetz, P | 1 |
| Schiattarella, GG | 2 |
| Sannino, A | 1 |
| Toscano, E | 1 |
| Giugliano, G | 1 |
| Gargiulo, G | 1 |
| Franzone, A | 1 |
| Trimarco, B | 2 |
| Esposito, G | 1 |
| Perrino, C | 1 |
| Guasch-Ferré, M | 1 |
| Ruiz-Canela, M | 1 |
| Bulló, M | 1 |
| Toledo, E | 1 |
| Corella, D | 1 |
| Gómez-Gracia, E | 1 |
| Fiol, M | 1 |
| Estruch, R | 1 |
| Lapetra, J | 1 |
| Fitó, M | 1 |
| Arós, F | 1 |
| Serra-Majem, L | 1 |
| Ros, E | 1 |
| Dennis, C | 1 |
| Liang, L | 1 |
| Clish, CB | 1 |
| Martínez-González, MA | 1 |
| Salas-Salvadó, J | 1 |
| Ascher, S | 1 |
| Reinhardt, C | 1 |
| Mafra, D | 2 |
| Borges, NA | 1 |
| Cardozo, LFMF | 1 |
| Anjos, JS | 1 |
| Black, AP | 1 |
| Moraes, C | 2 |
| Lindholm, B | 2 |
| Nowiński, A | 2 |
| Missimer, A | 1 |
| DiMarco, DM | 1 |
| Norris, GH | 1 |
| Blesso, CN | 2 |
| Murillo, AG | 1 |
| Vergara-Jimenez, M | 1 |
| Lemos, BS | 1 |
| Medina-Vera, I | 1 |
| Battson, ML | 1 |
| Lee, DM | 1 |
| Weir, TL | 1 |
| Gentile, CL | 1 |
| Schmedes, M | 1 |
| Brejnrod, AD | 1 |
| Aadland, EK | 1 |
| Kiilerich, P | 1 |
| Kristiansen, K | 1 |
| Jacques, H | 1 |
| Lavigne, C | 1 |
| Graff, IE | 1 |
| Eng, Ø | 1 |
| Holthe, A | 1 |
| Mellgren, G | 1 |
| Young, JF | 1 |
| Sundekilde, UK | 1 |
| Liaset, B | 1 |
| Bertram, HC | 1 |
| Cajka, T | 1 |
| Hurd, AG | 1 |
| Gu, X | 1 |
| Skye, SM | 1 |
| Roberts, AB | 1 |
| Shahen, CJ | 1 |
| Wagner, MA | 1 |
| Hartiala, JA | 1 |
| Kerby, RL | 1 |
| Obeid, S | 1 |
| Lüscher, TF | 1 |
| Allayee, H | 2 |
| Fiehn, O | 2 |
| Missailidis, C | 2 |
| Neogi, U | 1 |
| Nowak, P | 1 |
| Rhainds, D | 1 |
| Brodeur, MR | 1 |
| Tardif, JC | 1 |
| Haghikia, A | 2 |
| Liman, TG | 1 |
| Bledau, N | 1 |
| Schmidt, D | 1 |
| Zimmermann, F | 1 |
| Kränkel, N | 1 |
| Widera, C | 1 |
| Sonnenschein, K | 1 |
| Weissenborn, K | 1 |
| Fraccarollo, D | 1 |
| Heimesaat, MM | 1 |
| Bauersachs, J | 1 |
| Bavendiek, U | 1 |
| Endres, M | 1 |
| Landmesser, U | 1 |
| Manor, O | 1 |
| Zubair, N | 1 |
| Conomos, MP | 1 |
| Rohwer, JE | 1 |
| Krafft, CE | 1 |
| Lovejoy, JC | 1 |
| Magis, AT | 1 |
| Latkovskis, G | 2 |
| Makarova, E | 1 |
| Mazule, M | 1 |
| Bondare, L | 1 |
| Hartmane, D | 2 |
| Cirule, H | 1 |
| Grinberga, S | 2 |
| Erglis, A | 2 |
| Liepinsh, E | 2 |
| Dambrova, M | 2 |
| Janeiro, MH | 1 |
| Ramírez, MJ | 1 |
| Milagro, FI | 1 |
| Martínez, JA | 1 |
| Solas, M | 1 |
| Kanitsoraphan, C | 1 |
| Rattanawong, P | 1 |
| Charoensri, S | 1 |
| Wu, WK | 1 |
| Chen, CC | 1 |
| Liu, PY | 1 |
| Panyod, S | 1 |
| Liao, BY | 1 |
| Chen, PC | 1 |
| Kao, HL | 1 |
| Kuo, HC | 1 |
| Kuo, CH | 1 |
| Chiu, THT | 1 |
| Chen, RA | 1 |
| Chuang, HL | 1 |
| Huang, YT | 1 |
| Zou, HB | 1 |
| Hsu, CC | 1 |
| Chang, TY | 1 |
| Lin, CL | 1 |
| Ho, CT | 1 |
| Yu, HT | 1 |
| Sheen, LY | 1 |
| Wu, MS | 1 |
| Peng, J | 1 |
| Xiao, X | 1 |
| Hu, M | 1 |
| Al-Rubaye, H | 1 |
| Perfetti, G | 1 |
| Kaski, JC | 1 |
| Zheng, J | 1 |
| Xie, Y | 1 |
| Li, Z | 1 |
| Guo, X | 1 |
| Sun, G | 1 |
| Sun, Z | 1 |
| Xing, F | 1 |
| Caruso, D | 1 |
| Buonomo, G | 1 |
| D'Avino, M | 1 |
| Maisto, M | 2 |
| Schisano, C | 2 |
| Bocchino, B | 1 |
| Narciso, V | 1 |
| Stubbs, JR | 1 |
| Stedman, MR | 1 |
| Liu, S | 1 |
| Long, J | 1 |
| Franchetti, Y | 1 |
| West, RE | 1 |
| Prokopienko, AJ | 1 |
| Mahnken, JD | 1 |
| Chertow, GM | 2 |
| Nolin, TD | 1 |
| Jin, M | 1 |
| Qian, Z | 1 |
| Yin, J | 2 |
| Xu, W | 1 |
| Zhou, X | 2 |
| Cassambai, S | 1 |
| Salzano, A | 1 |
| Yazaki, Y | 1 |
| Bernieh, D | 1 |
| Wong, M | 1 |
| Israr, MZ | 1 |
| Heaney, LM | 2 |
| Suzuki, T | 2 |
| Park, JE | 1 |
| Miller, M | 1 |
| Rhyne, J | 1 |
| Kalagi, NA | 1 |
| Abbott, KA | 1 |
| Alburikan, KA | 1 |
| Alkofide, HA | 1 |
| Stojanovski, E | 1 |
| Garg, ML | 1 |
| Abbasi, J | 1 |
| Ge, X | 1 |
| Zhuang, R | 1 |
| Yu, P | 1 |
| Xu, Z | 1 |
| Liu, G | 1 |
| Xi, X | 1 |
| Fan, H | 1 |
| Tang, WH | 5 |
| Levison, BS | 3 |
| Britt, EB | 3 |
| Loscalzo, J | 1 |
| Stock, J | 1 |
| Miller, MJ | 1 |
| Ussher, JR | 1 |
| Lopaschuk, GD | 1 |
| Arduini, A | 1 |
| Brown, JM | 2 |
| Fan, Y | 1 |
| Khan, MS | 1 |
| Bawany, FI | 1 |
| Khan, A | 1 |
| Lever, M | 1 |
| George, PM | 1 |
| Slow, S | 1 |
| Bellamy, D | 1 |
| Young, JM | 1 |
| Ho, M | 1 |
| McEntyre, CJ | 1 |
| Elmslie, JL | 1 |
| Atkinson, W | 1 |
| Molyneux, SL | 1 |
| Troughton, RW | 1 |
| Frampton, CM | 1 |
| Richards, AM | 1 |
| Chambers, ST | 1 |
| Kaysen, GA | 1 |
| Johansen, KL | 1 |
| Dalrymple, LS | 1 |
| Kornak, J | 1 |
| Grimes, B | 1 |
| Dwyer, T | 1 |
| Chassy, AW | 1 |
| Fouque, D | 1 |
| Amaral, AC | 1 |
| Mente, A | 1 |
| Chalcraft, K | 1 |
| Ak, H | 1 |
| Davis, AD | 1 |
| Lonn, E | 1 |
| Miller, R | 1 |
| Potter, MA | 1 |
| Yusuf, S | 1 |
| Anand, SS | 1 |
| McQueen, MJ | 1 |
| Jones, DJ | 1 |
| Mbasu, RJ | 1 |
| Ng, LL | 1 |
| Aron-Wisnewsky, J | 1 |
| Clément, K | 1 |
| Hällqvist, J | 1 |
| Barany, P | 1 |
| Heimbürger, O | 1 |
| Obeid, R | 1 |
| Awwad, HM | 1 |
| Rabagny, Y | 1 |
| Graeber, S | 1 |
| Herrmann, W | 1 |
| Geisel, J | 1 |
| Nestvold, TK | 1 |
| Thoresen, H | 1 |
| Lappegård, KT | 1 |
| Kim, RB | 1 |
| Morse, BL | 1 |
| Djurdjev, O | 1 |
| Tang, M | 1 |
| Muirhead, N | 1 |
| Barrett, B | 1 |
| Holmes, DT | 1 |
| Madore, F | 1 |
| Clase, CM | 1 |
| Rigatto, C | 1 |
| Levin, A | 1 |
| Mondal, JA | 1 |
| Wang, S | 1 |
| Xia, GH | 1 |
| Liao, SX | 1 |
| Sheng, HF | 1 |
| Zhou, HW | 1 |
| Kuka, J | 1 |
| Strele, I | 1 |
| Konrade, I | 1 |
| Pugovics, O | 1 |
| Fennema, D | 1 |
| Phillips, IR | 1 |
| Shephard, EA | 1 |
| Albert, CM | 1 |
| Powe, NR | 1 |
| Meyer, TW | 1 |
| Hwang, S | 1 |
| Hai, X | 1 |
| Melamed, ML | 1 |
| Banerjee, T | 1 |
| Coresh, J | 1 |
| Chhibber-Goel, J | 1 |
| Singhal, V | 1 |
| Parakh, N | 1 |
| Bhargava, B | 1 |
| Sharma, A | 1 |
| Kalim, S | 1 |
| Velasquez, MT | 1 |
| Ramezani, A | 1 |
| Manal, A | 1 |
| Raj, DS | 1 |
| Weinert, CH | 1 |
| Empl, MT | 1 |
| Frommherz, L | 1 |
| Egert, B | 1 |
| Steinberg, P | 1 |
| Williams, PT | 1 |
| Lamendella, R | 1 |
| Faghihnia, N | 1 |
| Grube, A | 1 |
| Jansson, JK | 1 |
| Pham, K | 1 |
| Stremmel, W | 1 |
| Schmidt, KV | 1 |
| Schuhmann, V | 1 |
| Kratzer, F | 1 |
| Garbade, SF | 1 |
| Langhans, CD | 1 |
| Fricker, G | 1 |
| Okun, JG | 1 |
| Rak, K | 1 |
| Rader, DJ | 1 |
| Klipfell, E | 1 |
| Bennett, BJ | 1 |
| Koeth, R | 1 |
| Dugar, B | 1 |
| Feldstein, AE | 1 |
| Chung, YM | 1 |
| Schauer, P | 1 |
| Smith, JD | 1 |
| Lusis, AJ | 1 |
| Willyard, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| BASEL VIII Trial - Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia[NCT01838148] | 4,000 participants (Anticipated) | Observational | 2004-05-31 | Recruiting | |||
| Effects of a Whole Food Based Nutritional Formulation on Trimethylamine N-oxide and Cardiometabolic Endpoints in Healthy Adults.[NCT05795946] | 45 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | |||
| Concentration of Trimethylamine-N-oxide Versus Echocardiographic, Biochemical and Histopathological Parameters of Heart Failure in Patients With Severe Aortic Stenosis: a Prospective, Observatory Trial[NCT04406805] | 70 participants (Anticipated) | Observational | 2019-01-15 | Recruiting | |||
| Discovering the Effects of Pulses Through the Gut Microbiome and Bioavailability of Bioactive Compounds[NCT05999136] | 78 participants (Anticipated) | Interventional | 2023-10-02 | Recruiting | |||
| Impact of Facilitated Vegan Diet on Cardiometabolic Endpoints and Trimethylamine N-oxide[NCT05071196] | 70 participants (Anticipated) | Interventional | 2022-01-01 | Active, not recruiting | |||
| SWAP-MEAT (Study With Appetizing Plant-Food, Meat Eating Alternatives Trial) Athlete for MC-URC (Menus of Change University Research Collaborative): Three Diets on Athletic Performance[NCT06014307] | 120 participants (Anticipated) | Interventional | 2023-10-04 | Recruiting | |||
| SWAP-MEAT: Study With Appetizing Plant Food - Meat Eating Alternatives Trial[NCT03718988] | 38 participants (Actual) | Interventional | 2019-01-17 | Completed | |||
| Nurses' Health Study (Cardiovascular Component)[NCT00005152] | 121,700 participants (Actual) | Observational | 1980-08-31 | Active, not recruiting | |||
| "Plant-Based Meat vs Animal Red Meat: a Randomized Cross-over Trial"[NCT04510324] | 41 participants (Actual) | Interventional | 2020-11-01 | Completed | |||
| Investigation on the Effect of Carnitine Supplement on Gut Microbiota and TMAO Production Capacity[NCT02838732] | 56 participants (Actual) | Interventional | 2016-05-18 | Completed | |||
| A Randomised, Double-blinded, Cross-over, Placebo- Controlled Pilot Study to Investigate the Effect of Tomato Extract on TMAO in Overweight or Obese Adults[NCT04160481] | 37 participants (Actual) | Interventional | 2019-11-12 | Completed | |||
| Association Analysis of Cardiovascular and Nervous System Diseases and Intestinal Microbiome Based on Multi-omics Big Data and Related Applications[NCT06099496] | 490 participants (Anticipated) | Observational [Patient Registry] | 2023-04-01 | Recruiting | |||
| Effect of Choline Source and Gut Microbiota Composition on Trimethylamine-N-oxide Response in Humans[NCT04255368] | 44 participants (Actual) | Interventional | 2017-11-09 | Completed | |||
| Does the Human Gut Microbiome Serve as a Novel Personalized Therapeutic Target for Coronary Atherosclerosis?[NCT03009565] | 800 participants (Anticipated) | Observational | 2017-01-31 | Not yet recruiting | |||
| GutHeart: Targeting Gut Microbiota to Treat Heart Failure[NCT02637167] | Phase 2 | 150 participants (Anticipated) | Interventional | 2016-03-11 | Recruiting | ||
| Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)[NCT02016430] | 150 participants (Anticipated) | Interventional | 2014-04-04 | Recruiting | |||
| Analysis of MicroBial Metabolites After Eating Refined Food[NCT04308473] | 46 participants (Actual) | Interventional | 2020-09-01 | Active, not recruiting | |||
| Evaluation of Red Wine Effects Upon Gut Flora and Plasma Levels of Trimethylamine-N-oxide (TMAO) in Patients With Established Atherosclerotic Disease[NCT03232099] | 42 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| A Trial of the Ideal Protein System Versus Low Fat Diet for Weight Loss[NCT03515889] | 192 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| Effect of Probiotic Supplementation on Endothelial Function II[NCT03267758] | 215 participants (Anticipated) | Interventional | 2018-05-15 | Recruiting | |||
| Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People[NCT02586181] | 93 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes[NCT02588898] | 212 participants (Actual) | Observational | 2009-09-30 | Completed | |||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Low Fat Vegan Diet or American Heart Association Diet, Impact on Biomarkers of Inflammation, Oxidative Stress and Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol: A Four Week Randomized Trial[NCT01817491] | 60 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Effects of Choline Supplementation on Fetal Growth in Gestational Diabetes Mellitus[NCT04302168] | 60 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | |||
| Impact of Diet and Gut Microbiota on Trimethylamine-N-oxide Production and Fate in Humans[NCT02558673] | 40 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans (EGGS)[NCT03039023] | 86 participants (Actual) | Interventional | 2016-09-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Reduced Fat Vegan Diet | 0.22 |
| American Heart Association Diet | -0.16 |
Body mass index z-scores, also called BMI standard deviation (s.d.) scores, are measures of relative weight adjusted for child age and sex. Given a child's age, sex, BMI, and an appropriate reference standard, a BMI z-score (or its equivalent BMI-for-age percentile) can be determined. Negative BMI z-scores indicate a BMI that is lower than the population mean, while positive BMI scores indicate a value that is higher than the population mean. A decrease in the BMI z-score over time indicate a lowering of the BMI. Z-scores of 1.03 and 1.64 correspond to the 85th and 95th percentiles of BMI-for-age, which are the definitions of overweight and obesity in children. (NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | Z Score (Mean) |
|---|---|
| Reduced Fat Vegan Diet | -0.14 |
| American Heart Association Diet | -0.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | Z score (Mean) |
|---|---|
| PB/AHA | -0.13 |
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| PB/AHA | 0.39 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mm Hg (Mean) | |||
|---|---|---|---|---|
| Children Systolic BP | Parents Systolic BP | Children Diastolic BP | Parent Diastolic BP | |
| American Heart Association Diet | -5.14 | -3.14 | -4.36 | -6.64 |
| Reduced Fat Vegan Diet | -6.43 | -7.96 | -2.61 | -3.46 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | -0.08 | -0.73 |
| Reduced Fat Vegan Diet | -1.12 | -1.29 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | cm (Mean) | |||
|---|---|---|---|---|
| Children Waist Circumference | Parents Waist Circumference | Children Midarm Circumference | Parents Midarm Circumference | |
| American Heart Association Diet | -2.96 | -0.49 | -1.14 | 0.35 |
| Reduced Fat Vegan Diet | -1.53 | -1.94 | -2.02 | -1.32 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -.64 | -5.43 |
| Reduced Fat Vegan Diet | 0.93 | 4.93 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | 0.21 | 0.14 |
| Reduced Fat Vegan Diet | 0.17 | -0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/L (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | 2.78 | 0.21 |
| Reduced Fat Vegan Diet | -2.09 | -0.24 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -0.19 | -0.19 |
| Reduced Fat Vegan Diet | -0.17 | 0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | uU/ml (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | 3.16 | -3.15 |
| Reduced Fat Vegan Diet | -5.42 | -3.11 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| total cholesterol children | triglycerides children | high-density lipoprotein cholesterol children | low-density lipoprotein cholesterol children | total cholesterol parents | triglycerides parents | high-density lipoprotein cholesterol parents | low-density lipoprotein cholesterol parents | |
| American Heart Association Diet | -16.50 | -13.14 | -2.93 | -11.00 | -7.14 | 16.86 | 16.86 | -5.50 |
| Reduced Fat Vegan Diet | -22.50 | -25.50 | -5.93 | -13.14 | -33.79 | 6.21 | -8.14 | -27.00 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| alanine aminotransferase (ALT) children | aspartate aminotransferase (AST) children | alanine aminotransferase (ALT) parents | aspartate aminotransferase (AST) parents | |
| American Heart Association Diet | -1.14 | 0.00 | 4.57 | 4.43 |
| Reduced Fat Vegan Diet | 0.79 | 2.79 | 0.86 | 0.14 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | pmol/L (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -69.23 | 1.78 |
| Reduced Fat Vegan Diet | -75.34 | 16.91 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | -1.55 | -2.01 |
| Reduced Fat Vegan Diet | -3.05 | -3.64 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| Children adj mean ratio systolic BP | Children adj mean ratio diastolic BP | parents adj mean ratio systolic BP | parents adj mean ratio diastolic BP | |
| PB/AHA | 1.87 | 1.01 | 0.97 | 1.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | percentile (Mean) | |
|---|---|---|
| Children Change in BMI | Parents Change in BMI | |
| PB/AHA | -1.17 | -0.69 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | cm (Mean) | |||
|---|---|---|---|---|
| children waist circumference | parents waist circumference | children arm circumference | parents arm circumference | |
| PB/AHA | 1.32 | -1.14 | -1.25 | -1.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Children Weight | Parents Weight | |
| PB/AHA | -1.71 | -1.95 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| CHOL children | TRIG children | HDL children | LDL children | CHOL parents | TRIG parents | HDL parents | LDL parents | |
| PB/AHA | -10.34 | 1.01 | 0.17 | 0.95 | -27.29 | 0.95 | 0.94 | -21.92 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 1.01 | 1.06 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.99 | 0.96 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.46 | 0.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.26 | 1.14 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.7 | 0.87 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| ALT children | AST children | ALT parents | AST parents | |
| PB/AHA | 1 | 1.13 | 0.85 | 0.83 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.95 | 0.93 |
Changes in levels of non-labeled TMAO from baseline to Day 28 measured by established mass spectrometry techniques. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg in 24 hours (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 26.2 | 139.0 |
| Egg Whites + Choline Bitartrate Tablets | 29.3 | 186.9 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 27.5 | 221.8 |
| Phosphatidylcholine Capsules | 15.8 | 33.1 |
| Whole Hardboiled Eggs | 24.3 | 28.5 |
Changes in measured HDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 49 | 51 |
| Egg Whites + Choline Bitartrate Tablets | 48 | 50 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 57 | 56 |
| Phosphatidylcholine Capsules | 61 | 62 |
| Whole Hardboiled Eggs | 48 | 49 |
Changes in measured LDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 90 | 94 |
| Egg Whites + Choline Bitartrate Tablets | 104 | 101 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 108 | 118 |
| Phosphatidylcholine Capsules | 107 | 106 |
| Whole Hardboiled Eggs | 91 | 86 |
Changes in total cholesterol levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 180 | 172 |
| Egg Whites + Choline Bitartrate Tablets | 186 | 178 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 187 | 198 |
| Phosphatidylcholine Capsules | 175 | 172 |
| Whole Hardboiled Eggs | 156 | 158 |
Changes in measured triglyceride levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 106 | 96 |
| Egg Whites + Choline Bitartrate Tablets | 122 | 109 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 103 | 97 |
| Phosphatidylcholine Capsules | 74 | 84 |
| Whole Hardboiled Eggs | 86 | 100 |
Fasting plasma levels of betaine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 38.2 | 69.0 |
| Egg Whites + Choline Bitartrate Tablets | 38.7 | 59.8 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 30.7 | 46.9 |
| Phosphatidylcholine Capsules | 33.6 | 46.3 |
| Whole Hardboiled Eggs | 28.1 | 39.7 |
Fasting plasma levels of carnitine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 21.2 | 18.7 |
| Egg Whites + Choline Bitartrate Tablets | 21.1 | 18.9 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 21.5 | 15.6 |
| Phosphatidylcholine Capsules | 23.4 | 20.8 |
| Whole Hardboiled Eggs | 19.1 | 19.4 |
Fasting plasma levels of choline from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 7.5 | 12.9 |
| Egg Whites + Choline Bitartrate Tablets | 9.5 | 12.8 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 8.5 | 14.0 |
| Phosphatidylcholine Capsules | 7.6 | 10.6 |
| Whole Hardboiled Eggs | 8.3 | 10.9 |
Changes in levels of non-labeled TMAO from baseline to end-of-study (day 28) as measured by established techniques by mass spectrometry. (NCT03039023)
Timeframe: Baseline, 28 days
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 1.9 | 11.1 |
| Egg Whites + Choline Bitartrate Tablets | 2.6 | 28.1 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 2.3 | 12.3 |
| Phosphatidylcholine Capsules | 2.8 | 3.4 |
| Whole Hardboiled Eggs | 2.0 | 2.3 |
The activation and functioning of platelets within a single subject will be compared before and after increased choline intake. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | aggregation percentage (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 2.6 | 12.8 |
| Egg Whites + Choline Bitartrate Tablets | 3.0 | 29.4 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 2.3 | 12.3 |
| Phosphatidylcholine Capsules | 2.8 | 3.4 |
| Whole Hardboiled Eggs | 2.6 | 3.6 |
71 reviews available for trimethyloxamine and Cardiovascular Diseases
| Article | Year |
|---|---|
Polycystic ovary syndrome and cardiovascular risk. Could trimethylamine N-oxide (TMAO) be a major player? A potential upgrade forward in the DOGMA theory.
Topics: Animals; Bacteria; Cardiovascular Diseases; Dysbiosis; Female; Gastrointestinal Microbiome; Heart Di | 2021 |
Trimethylamine N-oxide-a marker for atherosclerotic vascular disease.
Topics: Animals; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Humans; Methylamines | 2021 |
Are eggs good again? A precision nutrition perspective on the effects of eggs on cardiovascular risk, taking into account plasma lipid profiles and TMAO.
Topics: Bacteria; Biological Variation, Population; Cardiovascular Diseases; Cholesterol; Choline; Diet; Egg | 2022 |
Association of Trimethylamine-N-Oxide Levels with Risk of Cardiovascular Disease and Mortality among Elderly Subjects: A Systematic Review and Meta-Analysis.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Methylamines; Oxides; Prospective | 2022 |
Gut microbiota-derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Gastrointestinal Microbiome; Humans; Hypertension; Methy | 2022 |
Trimethylamine N-oxide in cardiovascular disease.
Topics: Cardiovascular Diseases; Gastrointestinal Microbiome; Heart Failure; Humans; Methylamines | 2022 |
Trimethylamine N-oxide reduction is related to probiotic strain specificity: A systematic review.
Topics: Animals; Cardiovascular Diseases; Choline; Gastrointestinal Microbiome; Humans; Methylamines; Probio | 2022 |
[Gut-derived uremic toxin trimethylamine-N-oxide in cardiovascular disease under end-stage renal disease: an injury mechanism and therapeutic target].
Topics: Cardiovascular Diseases; Humans; Kidney Failure, Chronic; Methylamines; Oxides; Uremic Toxins | 2022 |
Trimethylamine N-Oxide Generated by the Gut Microbiota: Potential Atherosclerosis Treatment Strategies.
Topics: Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2022 |
The Role of Gut Microbiota and Trimethylamine N-oxide in Cardiovascular Diseases.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Gastrointestinal Microbiome; Humans; Methylamines; | 2023 |
Trimethylamine N-Oxide as a Potential Risk Factor for Non-communicable Diseases: A Systematic Review.
Topics: Animals; Cardiovascular Diseases; Cross-Sectional Studies; Noncommunicable Diseases; Risk Factors | 2023 |
Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease?
Topics: Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines; Prospec | 2023 |
Microbiota Effect on Trimethylamine N-Oxide Production: From Cancer to Fitness-A Practical Preventing Recommendation and Therapies.
Topics: Animals; Cardiovascular Diseases; Choline; Inflammation; Methylamines; Microbiota; Neoplasms | 2023 |
The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases.
Topics: Atherosclerosis; Cardiovascular Diseases; Choline; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis.
Topics: Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Inflammation; Renal Insufficiency, Chr | 2023 |
The interplay between microbial metabolites and macrophages in cardiovascular diseases: A comprehensive review.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Humans; Macrophages; Methylamines | 2023 |
Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD).
Topics: Atherosclerosis; Cardiovascular Diseases; Dysbiosis; Gastrointestinal Microbiome; Humans; Inflammati | 2023 |
Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?
Topics: Cardiovascular Diseases; Gastrointestinal Microbiome; Heart Failure; Humans; Methylamines | 2023 |
The Microbial Metabolite Trimethylamine N-Oxide Links Vascular Dysfunctions and the Autoimmune Disease Rheumatoid Arthritis.
Topics: Amyloid; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Cardiovascular Diseases; Diet; Dysbios | 2019 |
The emerging role of gut microbial metabolism on cardiovascular disease.
Topics: Animals; Bacteria; Cardiovascular Diseases; Diet; Gastrointestinal Microbiome; Humans; Metabolomics; | 2019 |
Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics.
Topics: Animals; Bacteria; Cardiovascular Diseases; Dysbiosis; Endotoxemia; Gastrointestinal Microbiome; Hea | 2020 |
Archaea, specific genetic traits, and development of improved bacterial live biotherapeutic products: another face of next-generation probiotics.
Topics: Animals; Archaea; Biological Therapy; Cardiovascular Diseases; Diet; Gastrointestinal Microbiome; Hu | 2020 |
Trimethylamine N-Oxide in Relation to Cardiometabolic Health-Cause or Effect?
Topics: Age Factors; Amines; Animals; Cardiometabolic Risk Factors; Cardiovascular Diseases; Carnitine; Dige | 2020 |
Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy.
Topics: Animals; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Life Style; Methylamines; Mic | 2020 |
Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review).
Topics: Amino Acids; Animals; Bile Acids and Salts; Cardiovascular Diseases; Fatty Acids; Gastrointestinal M | 2020 |
Gut Microbiota and Cardiovascular Disease.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Cardiovascular Diseases; Carnitine; Choline; Disease | 2020 |
The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases.
Topics: Animals; Biological Availability; Cardiovascular Diseases; Choline; Diet; Dysbiosis; Gastrointestina | 2020 |
TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Methylamines; Risk Factors | 2021 |
Molecular Mechanisms Underlying the Cardiovascular Toxicity of Specific Uremic Solutes.
Topics: Basic Helix-Loop-Helix Transcription Factors; Blood Platelets; Cardiovascular Diseases; Disease Prog | 2020 |
Implication of Gut Microbiota in Cardiovascular Diseases.
Topics: Cardiovascular Diseases; Cell Death; Energy Metabolism; Fatty Acids, Volatile; Gastrointestinal Micr | 2020 |
Understanding connections and roles of gut microbiome in cardiovascular diseases.
Topics: Bacteria; Bile Acids and Salts; Cardiovascular Diseases; Diet; Fatty Acids, Volatile; Gastrointestin | 2021 |
Gut microbiota-associated trimethylamine N-oxide and increased cardiometabolic risk in adults: a systematic review and dose-response meta-analysis.
Topics: Adult; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines; Risk Factors | 2021 |
Gut microbiota-derived trimethylamine-N-oxide: A bridge between dietary fatty acid and cardiovascular disease?
Topics: Cardiovascular Diseases; Fatty Acids; Gastrointestinal Microbiome; Humans; Methylamines; Oxides | 2020 |
Role of Gut Microbiota and Their Metabolites on Atherosclerosis, Hypertension and Human Blood Platelet Function: A Review.
Topics: Animals; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Fatty Acids, Volatile; Gastroint | 2021 |
Use of dietary phytochemicals for inhibition of trimethylamine N-oxide formation.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Drug Discovery; Gastrointestinal Microbiome; Huma | 2021 |
Trimethylamine N-Oxide (TMAO), Diet and Cardiovascular Disease.
Topics: Cardiovascular Diseases; Choline; Diet; Humans; Methylamines | 2021 |
Trimethylamine N-oxide (TMAO): a new attractive target to decrease cardiovascular risk.
Topics: Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Methylamines; Risk Factors | 2022 |
Two Gut Microbiota-Derived Toxins Are Closely Associated with Cardiovascular Diseases: A Review.
Topics: Bacterial Toxins; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Lipopolysaccharides; | 2021 |
Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases.
Topics: Animals; Bacteria; Cardiovascular Diseases; Diet; Gastrointestinal Microbiome; Heart Disease Risk Fa | 2021 |
Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.
Topics: Animals; Cardiovascular Diseases; Disease Progression; Dysbiosis; Gastrointestinal Microbiome; Glyca | 2021 |
Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.
Topics: Cardiovascular Diseases; Carnitine; Choline; Diet; Gastrointestinal Microbiome; Humans; Methylamines | 2017 |
Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Gastrointestinal Microbiome; Humans; Meth | 2017 |
Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Gastrointestinal Microbiome; Humans; Meth | 2017 |
Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Gastrointestinal Microbiome; Humans; Meth | 2017 |
Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Gastrointestinal Microbiome; Humans; Meth | 2017 |
Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Humans; Male; Methylamines; Middle Aged; P | 2018 |
The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease.
Topics: Biomarkers; Cardiovascular Diseases; Diet Therapy; Gastrointestinal Microbiome; Humans; Kidney; Lipi | 2017 |
Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Dose-Response Relationship, Drug; Female; | 2017 |
The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease.
Topics: Animals; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Gastr | 2018 |
Red meat intake in chronic kidney disease patients: Two sides of the coin.
Topics: Cardiovascular Diseases; Diet, Protein-Restricted; Dietary Fats; Dietary Proteins; Gastrointestinal | 2018 |
Trimethylamine N-oxide: A harmful, protective or diagnostic marker in lifestyle diseases?
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Diet; Gastrointestinal Microbiome; Homeostas | 2018 |
The gut microbiota as a novel regulator of cardiovascular function and disease.
Topics: Aging; Animals; Anti-Bacterial Agents; Atherosclerosis; Bile Acids and Salts; Cardiovascular Disease | 2018 |
Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.
Topics: Animals; Cardiovascular Diseases; Cresols; Diet Therapy; Dietary Supplements; Dysbiosis; Enzyme Inhi | 2018 |
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Topics: Animals; Apolipoproteins; Biomarkers; Cardiovascular Diseases; Dyslipidemias; Gastrointestinal Micro | 2018 |
Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Inflammation Mediators; Metabolic Networks and Pathways | 2018 |
Trimethylamine N-Oxide and Risk of Cardiovascular Disease and Mortality.
Topics: Animals; Bacteria; Biomarkers; Cardiovascular Diseases; Cause of Death; Gastrointestinal Microbiome; | 2018 |
Interaction between gut microbiome and cardiovascular disease.
Topics: Cardiovascular Diseases; Fatty Acids, Volatile; Fecal Microbiota Transplantation; Gastrointestinal M | 2018 |
The Role of Microbiota in Cardiovascular Risk: Focus on Trimethylamine Oxide.
Topics: Cardiovascular Diseases; Cause of Death; Global Health; Humans; Methylamines; Microbiota; Morbidity; | 2019 |
The role of intestinal microbiota in cardiovascular disease.
Topics: Bile Acids and Salts; Cardiovascular Diseases; Dysbiosis; Fatty Acids; Gastrointestinal Microbiome; | 2019 |
Modulation of Circulating Trimethylamine N-Oxide Concentrations by Dietary Supplements and Pharmacological Agents: A Systematic Review.
Topics: Anti-Bacterial Agents; Antioxidants; Cardiovascular Diseases; Carnitine; Choline; Dietary Supplement | 2019 |
The Gut Microbial Metabolite Trimethylamine N-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis.
Topics: Adult; Aged; Bacteria; Cardiovascular Diseases; Female; Gastrointestinal Microbiome; Humans; Hyperte | 2020 |
Gut microbiota metabolism of L-carnitine and cardiovascular risk.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Diet; Dietary Supplements; Humans; Ins | 2013 |
Metaorganismal nutrient metabolism as a basis of cardiovascular disease.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Diet; Humans; Methylamines; Risk | 2014 |
The contributory role of gut microbiota in cardiovascular disease.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Choline; Diet; Female; Food; Humans; I | 2014 |
The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases.
Topics: Bacteria; Cardiovascular Diseases; Diet; Endocrine System; Humans; Intestines; Methylamines; Microbi | 2015 |
Egg phospholipids and cardiovascular health.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Diet; Eggs; G | 2015 |
Trimethylamine N-Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet.
Topics: Animals; Cardiovascular Diseases; Carnitine; Choline; Diet, Protein-Restricted; Disease Models, Anim | 2015 |
The gut microbiome, diet, and links to cardiometabolic and chronic disorders.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Chronic Disease; Diet; Gastrointestinal Microbiome; Hu | 2016 |
Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease.
Topics: Animals; Cardiovascular Diseases; Gastrointestinal Microbiome; Host-Pathogen Interactions; Humans; M | 2016 |
Microbiome, trimethylamine N-oxide, and cardiometabolic disease.
Topics: Animals; Cardiovascular Diseases; Humans; Metabolic Diseases; Methylamines; Microbiota | 2017 |
The Metabolite Trimethylamine-N-Oxide is an Emergent Biomarker of Human Health.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Drugs, Chinese Herbal; Humans; Kidney Diseases; Methyl | 2017 |
An overview of renal metabolomics.
Topics: Acute Kidney Injury; Analytic Sample Preparation Methods; Cardiovascular Diseases; Diabetic Nephropa | 2017 |
Trimethylamine N-Oxide: The Good, the Bad and the Unknown.
Topics: Animals; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines; Renal Insuffici | 2016 |
12 trials available for trimethyloxamine and Cardiovascular Diseases
91 other studies available for trimethyloxamine and Cardiovascular Diseases
| Article | Year |
|---|---|
Association of plasma trimethylamine N-oxide levels with atherosclerotic cardiovascular disease and factors of the metabolic syndrome.
Topics: Adult; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Humans; Metabolic Syndrome; Methylamine | 2021 |
Trimethylamine
Topics: Animals; Cardiovascular Diseases; Cells, Cultured; Gene Expression Regulation; Hep G2 Cells; Humans; | 2021 |
Trimethylamine-N-oxide (TMAO) and clinical outcomes in patients with end-stage kidney disease receiving peritoneal dialysis.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Kidney Failure, Chronic; Oxides; Peritoneal Dialysis; P | 2022 |
The Dietary Nutrient Trimethylamine
Topics: Animals; Cardiovascular Diseases; Dietary Supplements; Humans; Lipid Bilayers; Methylamines; Nutrien | 2021 |
The microbial gbu gene cluster links cardiovascular disease risk associated with red meat consumption to microbiota L-carnitine catabolism.
Topics: Animals; Cardiovascular Diseases; Carnitine; Clostridiales; Feces; Female; Gastrointestinal Microbio | 2022 |
Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD).
Topics: Betaine; Cardiovascular Diseases; Carnitine; Choline; Coronary Artery Disease; Gastrointestinal Micr | 2022 |
Association of Uremic Solutes With Cardiovascular Death in Diabetic Kidney Disease.
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Nephropathies; Humans; Me | 2022 |
Transferrin predicts trimethylamine-N-oxide levels and is a potential biomarker of cardiovascular disease.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Methylamines; Oxides; Transferrin | 2022 |
Association of Trimethylamine N-Oxide and Metabolites With Mortality in Older Adults.
Topics: Aged; Betaine; Cardiovascular Diseases; Carnitine; Choline; Cohort Studies; Female; Humans; Male; Me | 2022 |
Citrulline and long-term mortality in patients with cardiovascular disease.
Topics: Acute Coronary Syndrome; Biomarkers; Cardiovascular Diseases; Citrulline; Female; Humans; Male; Midd | 2022 |
Relation of Statin Use to Gut Microbial Trimethylamine N-Oxide and Cardiovascular Risk.
Topics: Cardiovascular Diseases; Gastrointestinal Microbiome; Heart Disease Risk Factors; Humans; Hydroxymet | 2022 |
Dietary Meat, Trimethylamine N-Oxide-Related Metabolites, and Incident Cardiovascular Disease Among Older Adults: The Cardiovascular Health Study.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Humans; Meat; Methylamines; Risk Facto | 2022 |
All-Cause Mortality and Trimethylamine N-Oxide Levels in Patients with Cardiovascular Disease.
Topics: Atrial Fibrillation; Biomarkers; Cardiovascular Diseases; Female; Heart Failure; Humans; Male; Methy | 2022 |
Serum Trimethylamine N-Oxide Level Is Associated with Peripheral Arterial Stiffness in Advanced Non-Dialysis Chronic Kidney Disease Patients.
Topics: Ankle Brachial Index; C-Reactive Protein; Cardiovascular Diseases; Humans; Methylamines; Pulse Wave | 2022 |
Increased plasma trimethylamine-
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cognitive Dysfunction; Heart Disease Risk | 2022 |
Initiation of 3,3-dimethyl-1-butanol at midlife prevents endothelial dysfunction and attenuates in vivo aortic stiffening with ageing in mice.
Topics: Aging; Animals; Butanols; Cardiovascular Diseases; Drinking Water; Endothelium, Vascular; Humans; Mi | 2022 |
TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis.
Topics: Animals; Atherosclerosis; Betaine; Cardiovascular Diseases; Carnitine; Choline; Humans; Inflammation | 2022 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Association of Circulating Trimethylamine-N Oxide With Malnutrition and the Risk of Coronary Artery Disease in Patients With Maintenance Hemodialysis.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Humans; Malnutrition; Oxides; Renal Dialysis | 2023 |
Trimethylamine N-oxide is associated with long-term mortality risk: the multi-ethnic study of atherosclerosis.
Topics: Adult; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Dementia; Humans; Methylamines; Neoplas | 2023 |
Cardiovascular disease risk prediction in scleroderma.
Topics: Biomarkers; Cardiac Myosins; Cardiovascular Diseases; Female; Humans; Troponin T | 2023 |
Choline and trimethylamine N-oxide supplementation in normal chow diet and western diet promotes the development of atherosclerosis in Apoe -/- mice through different mechanisms.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cardiovascular Diseases; Choline; Diet, Western; Dietar | 2023 |
A gut microbiome metabolite paradoxically depresses contractile function while activating mitochondrial respiration.
Topics: Animals; Cardiovascular Diseases; Gastrointestinal Microbiome; Glycogen Synthase Kinase 3 beta; Male | 2023 |
Trimethylamine N-Oxide (TMAO) Inducing Endothelial Injury: UPLC-MS/MS-Based Quantification and the Activation of Cathepsin B-Mediated NLRP3 Inflammasome.
Topics: Animals; Cardiovascular Diseases; Cathepsin B; Cells, Cultured; Chromatography, High Pressure Liquid | 2023 |
Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Arginine; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; D | 2023 |
Identification of Polymethoxyflavones (PMFs) from Orange Peel and Their Inhibitory Effects on the Formation of Trimethylamine (TMA) and Trimethylamine-N-oxide (TMAO) Using cntA/B and cutC/D Enzymes and Molecular Docking.
Topics: Cardiovascular Diseases; Citrus sinensis; Methylamines; Molecular Docking Simulation; Oxides | 2023 |
Trimethylamine But Not Trimethylamine Oxide Increases With Age in Rat Plasma and Affects Smooth Muscle Cells Viability.
Topics: Age Factors; Animals; Cardiovascular Diseases; Cell Culture Techniques; Cell Survival; Gastrointesti | 2020 |
TMA, A Forgotten Uremic Toxin, but Not TMAO, Is Involved in Cardiovascular Pathology.
Topics: Adult; Aged; Animals; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cell Survival; Cell | 2019 |
Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome.
Topics: Adolescent; Adult; Betaine; Blood Glucose; Cardiovascular Diseases; Carnitine; Choline; Female; Gast | 2019 |
[Trimethylamine-N-oxide and cardiovascular events in chronic kidney disease].
Topics: Biomarkers; Cardiovascular Diseases; Humans; Methylamines; Oxides; Renal Insufficiency, Chronic | 2019 |
Trimethylamine N-Oxide and Adenosine Diphosphate-Induced Platelet Reactivity Are Independent Risk Factors for Cardiovascular and All-Cause Mortality.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Methylamines; Mortality; Platelet Activation; Thrombosi | 2020 |
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation.
Topics: Adult; Anti-Retroviral Agents; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Carotid Intima- | 2020 |
Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study.
Topics: Adiposity; Aged; Bacteria; Betaine; Biomarkers; Cardiovascular Diseases; Carnitine; Choline; Cohort | 2020 |
[Research progress of targeting gut microbiota-TMA-TMAO pathway in cardiovascular diseases].
Topics: Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines | 2020 |
Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Male; Methylamines; Middle | 2020 |
Population studies of TMAO and its precursors may help elucidate mechanisms.
Topics: Adiposity; Betaine; Biomarkers; Cardiovascular Diseases; Carnitine; Choline; Humans; Methylamines; M | 2020 |
Topics: Aged; Amines; Amino Acids; Biomarkers; Carbonic Anhydrases; Cardiovascular Diseases; Catalysis; Cros | 2021 |
TMAO: Trimethylamine-N-Oxide or Time to Minimize Intake of Animal Products?
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Methylamines; Oxides; Plasma | 2020 |
Trimethylamine
Topics: Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines; Microbiota | 2021 |
Association of trimethylamine
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; China; Comorbidity; Female; Humans | 2020 |
Trimethylamine N-Oxide, a Gut Microbiota-Dependent Metabolite, is Associated with Frailty in Older Adults with Cardiovascular Disease.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cognition Disorders; Cross-Sectional S | 2020 |
Trimethylamine N-oxide and the reverse cholesterol transport in cardiovascular disease: a cross-sectional study.
Topics: Aged; Biological Transport; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cholesterol | 2020 |
Insights in the regulation of trimetylamine N-oxide production using a comparative biomimetic approach suggest a metabolic switch in hibernating bears.
Topics: Adult; Aged; Aged, 80 and over; Animals; Betaine; Biomimetics; Cardiovascular Diseases; Choline; Fem | 2020 |
Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria.
Topics: Aged; Albuminuria; Biomarkers; Cardiovascular Diseases; Cohort Studies; Denmark; Diabetes Mellitus, | 2021 |
Dietary factors, gut microbiota, and serum trimethylamine-N-oxide associated with cardiovascular disease in the Hispanic Community Health Study/Study of Latinos.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Diet; Female; Gastrointes | 2021 |
Trimethylamine N-oxide variation in humans: the product of a diet-microbiota interaction?
Topics: Cardiovascular Diseases; Diet; Gastrointestinal Microbiome; Hispanic or Latino; Humans; Methylamines | 2021 |
Interplay between diet and gut microbiome, and circulating concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men.
Topics: Cardiovascular Diseases; Choline; Diet; Gastrointestinal Microbiome; Humans; Male; Methylamines | 2022 |
Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Cardiovascular Diseases; Case-Control Studies; Female; Gas | 2021 |
Pathogenic Mechanisms of Trimethylamine N-Oxide-induced Atherosclerosis and Cardiomyopathy.
Topics: Animals; Atherosclerosis; Betaine; Cardiomyopathies; Cardiovascular Diseases; Humans; Methylamines | 2022 |
HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation.
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Chromatography, High Pressure L | 2017 |
NMR quantification of trimethylamine-N-oxide in human serum and plasma in the clinical laboratory setting.
Topics: Adult; Cardiovascular Diseases; Female; Humans; Magnetic Resonance Spectroscopy; Male; Methylamines; | 2017 |
Microbiota-dependent metabolite and cardiovascular disease marker trimethylamine-N-oxide (TMAO) is associated with monocyte activation but not platelet function in untreated HIV infection.
Topics: Adult; Betaine; Biomarkers; Blood Platelets; Cardiovascular Diseases; Carnitine; Choline; Cross-Sect | 2017 |
What Are Missing Parts in the Research Story of Trimethylamine-N-oxide (TMAO)?
Topics: Animals; Cardiovascular Diseases; Cattle; Gastrointestinal Microbiome; Humans; Intestinal Mucosa; In | 2017 |
Associations of current diet with plasma and urine TMAO in the KarMeN study: direct and indirect contributions.
Topics: Adult; Animals; Biomarkers; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Cross-Sec | 2017 |
Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk.
Topics: Aged; Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Cholesterol; Choline; Disease Mo | 2018 |
The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages.
Topics: Adult; Aged; Bacterial Translocation; Cardiovascular Diseases; Cluster Analysis; DNA, Bacterial; DNA | 2018 |
Gut Microbiota-Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Brain Ischemia; Cardiovascular Disea | 2018 |
A Multi-omic Association Study of Trimethylamine N-Oxide.
Topics: Atherosclerosis; Cardiovascular Diseases; Female; Gastrointestinal Microbiome; Humans; Male; Methyla | 2018 |
Loop diuretics decrease the renal elimination rate and increase the plasma levels of trimethylamine-N-oxide.
Topics: Aged; Animals; Biomarkers; Cardiovascular Agents; Cardiovascular Diseases; Cross-Sectional Studies; | 2018 |
Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice.
Topics: Animals; Cardiovascular Diseases; Carnitine; Diet; Dysbiosis; Feeding Behavior; Gastrointestinal Mic | 2019 |
Serum gut microbe-dependent trimethylamine N-oxide improves the prediction of future cardiovascular disease in a community-based general population.
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Chromatography, Liquid; Female; Follow-Up Studi | 2019 |
Trimethylamine
Topics: Adult; Aged; Angina, Unstable; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Hos | 2019 |
Impact of acute choline loading on circulating trimethylamine N-oxide levels.
Topics: Biomarkers; Cardiovascular Diseases; Choline; Diet; Healthy Volunteers; Humans; Lipotropic Agents; M | 2019 |
Differential effect of short-term popular diets on TMAO and other cardio-metabolic risk markers.
Topics: Amino Acids, Branched-Chain; Bacteria; Biomarkers; Cardiovascular Diseases; Diet, Fat-Restricted; Di | 2019 |
TMAO and Heart Disease: The New Red Meat Risk?
Topics: Cardiovascular Diseases; Carnitine; Diet; Fatty Acids; Gastrointestinal Microbiome; Humans; Methylam | 2019 |
Microbial metabolites as predictive biomarkers: a paradigm shift for cardiovascular risk stratification.
Topics: Acute Coronary Syndrome; Biomarkers; Cardiovascular Diseases; Humans; Lysine; Methylamines; Prognosi | 2019 |
Is increased plasma TMAO a compensatory response to hydrostatic and osmotic stress in cardiovascular diseases?
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Carnitine; Choline; Diet; Humans; Hydrostat | 2019 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Gut microbiota, the genome, and diet in atherogenesis.
Topics: Anti-Bacterial Agents; Cardiovascular Diseases; Female; Humans; Intestines; Male; Metagenome; Methyl | 2013 |
Gut microbiota: an environmental risk factor for cardiovascular disease.
Topics: Cardiovascular Diseases; Choline; Diet, Mediterranean; Environment; Environmental Pollutants; Humans | 2013 |
Risk factors for cardiovascular disease: a cautionary tale of diet-microbiome interactions.
Topics: Cardiovascular Diseases; Carnitine; Choline; Diet; Gastrointestinal Tract; Humans; Methylamines; Mic | 2013 |
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide.
Topics: Animals; Betaine; Cardiovascular Diseases; Choline; Female; Humans; Intestinal Mucosa; Kaplan-Meier | 2014 |
Intestinal microbiota produced trimethylamine-N-oxide can increase the risk of cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Intestinal Mucosa; Intestines; Methylamines; Microbiota; Oxidants; | 2014 |
Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Betaine; Biomarkers; Cardiovascular Diseases; Case | 2014 |
Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Chromatography, Liquid; Cohort Studies; Com | 2015 |
The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada.
Topics: Canada; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Male; Methylamines; Middle | 2015 |
High mass accuracy assay for trimethylamine N-oxide using stable-isotope dilution with liquid chromatography coupled to orthogonal acceleration time of flight mass spectrometry with multiple reaction monitoring.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Female; Humans; Indicator Dilution | 2016 |
Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease.
Topics: Adult; Aged; Betaine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Choline; Female; Fibr | 2016 |
Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism.
Topics: Aged; Bacteria; Betaine; Cardiovascular Diseases; Choline; Creatinine; Diabetes Mellitus; Female; Ga | 2016 |
Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism.
Topics: Aged; Bacteria; Betaine; Cardiovascular Diseases; Choline; Creatinine; Diabetes Mellitus; Female; Ga | 2016 |
Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism.
Topics: Aged; Bacteria; Betaine; Cardiovascular Diseases; Choline; Creatinine; Diabetes Mellitus; Female; Ga | 2016 |
Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism.
Topics: Aged; Bacteria; Betaine; Cardiovascular Diseases; Choline; Creatinine; Diabetes Mellitus; Female; Ga | 2016 |
Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery.
Topics: Adult; Atherosclerosis; Bariatric Surgery; Betaine; Body Mass Index; Cardiovascular Diseases; Carnit | 2016 |
Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events.
Topics: Aged; Aged, 80 and over; Biomarkers; Canada; Cardiovascular Diseases; Disease-Free Survival; Female; | 2016 |
Effect of Trimethylamine N-Oxide on Interfacial Electrostatics at Phospholipid Monolayer-Water Interfaces and Its Relevance to Cardiovascular Disease.
Topics: Cardiovascular Diseases; Cell Membrane; Endothelial Cells; Humans; Methylamines; Phospholipids; Stat | 2016 |
[Distribution characteristics of trimethylamine N-oxide and its association with gut microbiota].
Topics: Adult; Atherosclerosis; Bacteria; Biomarkers; Cardiovascular Diseases; Chromatography, Liquid; Gastr | 2016 |
Diabetes is Associated with Higher Trimethylamine N-oxide Plasma Levels.
Topics: Age Factors; Aged; Animals; Body Mass Index; Cardiovascular Diseases; Carnitine; Diabetes Mellitus; | 2016 |
Dietary phosphatidylcholine and risk of all-cause and cardiovascular-specific mortality among US women and men.
Topics: Adult; Cardiovascular Diseases; Cohort Studies; Diabetes Complications; Diet; Female; Humans; Male; | 2016 |
The influence of a chronic L-carnitine administration on the plasma metabolome of male Fischer 344 rats.
Topics: Animals; Carcinogens; Cardiovascular Diseases; Carnitine; Dietary Supplements; Dose-Response Relatio | 2017 |
The gut-blood barrier permeability - A new marker in cardiovascular and metabolic diseases?
Topics: Biomarkers; Cardiovascular Diseases; Cardiovascular System; Gastrointestinal Microbiome; Homeostasis | 2017 |
Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small Intestine.
Topics: Aged; Cardiovascular Diseases; Gas Chromatography-Mass Spectrometry; Humans; Intestine, Small; Male; | 2017 |
Cardiovascular disease: the diet-microbe morbid union.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Choline; Diet; Dietary Fats; | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Pathology: At the heart of the problem.
Topics: Animals; Bacteria; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diet; Gastrointestin | 2013 |